Cannabis in Palliative Care

Not medical advice

This article is educational, not medical advice. Palliative care decisions involve complex interactions between disease, medications, and personal goals. Talk to a palliative care physician or oncologist before starting, stopping, or changing cannabis use — especially if you are taking opioids, benzodiazepines, anticoagulants, or chemotherapy. Cannabis interacts with many drugs metabolized by CYP3A4 and CYP2C9 Strong evidence.

Plain-language summary

Palliative care focuses on quality of life for people with serious illness — relieving pain, nausea, anxiety, poor appetite, and distress, regardless of whether the underlying disease can be cured. Cannabis and cannabinoid medicines (THC, CBD, and synthetic versions like dronabinol and nabilone) are sometimes used as add-on therapy when standard treatments fall short.

The honest picture: cannabis is not a miracle drug for dying patients, but it is also not nothing. The best-supported use is preventing nausea and vomiting from chemotherapy. For pain and appetite, the evidence is real but modest — often smaller effects than patients or families hope for ^[1][2]. For anxiety, sleep, and 'existential distress,' there is almost no controlled evidence, only patient reports.

In palliative settings, the risk calculus changes. Side effects that would disqualify a drug for a healthy 30-year-old (drowsiness, mild cognitive slowing) may be acceptable or even welcome at end of life.

What probably works

Chemotherapy-induced nausea and vomiting (CINV). This is the strongest indication. Synthetic THC analogs nabilone and dronabinol are FDA-approved for CINV refractory to standard antiemetics. A 2015 systematic review and meta-analysis in JAMA found cannabinoids more effective than placebo for CINV, though the quality of evidence was rated moderate ^[1]. Modern 5-HT3 antagonists (ondansetron) and NK1 antagonists (aprepitant) are usually tried first; cannabinoids are second- or third-line Strong evidence.

Chronic pain as part of a multimodal regimen. The National Academies' 2017 report concluded there is substantial evidence that cannabis is effective for chronic pain in adults ^[2]. Effect sizes are modest — roughly a 30% reduction in pain in about 30% of patients, comparable to gabapentinoids. For cancer pain specifically, nabiximols (Sativex, a THC:CBD oromucosal spray) has shown modest benefit as an adjunct to opioids in some trials, though later phase III trials were largely negative ^[3] Disputed.

What might work

Appetite stimulation and cachexia. Dronabinol is FDA-approved for AIDS-related anorexia. In cancer cachexia, results are mixed — a randomized trial comparing cannabis extract, THC alone, and placebo found no significant appetite or quality-of-life difference ^[4] Weak / limited. Some patients clearly benefit; population averages are unimpressive.

Sleep. Many palliative patients report cannabis helps them sleep. Controlled data is limited and often confounded by pain relief (less pain = better sleep) Weak / limited. THC reduces REM sleep, which has unclear implications in end-of-life care.

Anxiety and mood at end of life. Plausible mechanism, real patient testimonials, almost no controlled trials in palliative populations Anecdote. CBD has anxiolytic effects in experimental anxiety models in healthy adults, but extrapolating to dying patients is a leap Weak / limited.

Opioid-sparing. Observational studies suggest some patients reduce opioid doses when adding cannabis. Randomized data is much weaker and inconsistent Disputed. This is an active research area, not settled science.

What doesn't work, or has weak evidence

Curing or slowing cancer. Preclinical (cell and animal) studies show cannabinoids can kill some cancer cell lines. There is no good human evidence that cannabis treats cancer in living patients No data. Patients sometimes refuse standard therapy in favor of cannabis oil protocols promoted online; this is a documented harm ^[5].

Dyspnea (breathlessness). No controlled evidence cannabis helps the air-hunger common in end-stage lung disease or heart failure No data. Smoke inhalation can worsen respiratory symptoms.

'Indica for nighttime, sativa for daytime.' This is dispensary folklore, not pharmacology. The indica/sativa distinction does not reliably predict effects in patients Disputed. Cannabinoid and terpene content vary widely within both categories ^[6].

Specific strain claims for specific symptoms. Marketing rather than evidence. Choose by cannabinoid ratio (THC:CBD), dose, and route — not by strain name No data.

What we don't know

• Optimal dosing for frail, elderly, or opioid-tolerant patients.
• Whether CBD-dominant products help anxiety or sleep at end of life specifically.
• Long-term effects in palliative populations — usually irrelevant given prognosis, but relevant in chronic non-malignant disease.
• Drug-drug interactions in patients on 10+ medications. CBD inhibits CYP3A4 and CYP2C9; this can raise levels of warfarin, certain chemotherapeutics, and many opioids Strong evidence^[7].
• Whether cannabis genuinely reduces 'existential' or 'spiritual' distress, or just sedates patients into not reporting it. This matters ethically.

Comparison with standard treatments

For CINV: 5-HT3 antagonists (ondansetron) and NK1 antagonists (aprepitant) are first-line and more effective than cannabinoids for most patients. Cannabinoids are useful when these fail ^[1].

For cancer pain: Opioids remain the cornerstone. Cannabis is an adjunct that may allow modest opioid dose reduction in some patients but does not replace opioids for severe pain ^[2][3].

For appetite: Megestrol acetate and corticosteroids have larger effects on appetite than cannabinoids, though with their own side effects (thromboembolism, hyperglycemia) Strong evidence.

For anxiety/insomnia: Benzodiazepines and low-dose antipsychotics (e.g., olanzapine) have stronger evidence in palliative care. Cannabis may be reasonable when these cause problematic side effects.

The practical role of cannabis is usually adjunctive: layered onto standard therapy to reduce doses, manage refractory symptoms, or address multiple symptoms with one agent.

Risks

• Sedation and falls. Particularly with THC, particularly in elderly patients on opioids or benzodiazepines Strong evidence. Falls are a major cause of injury in palliative populations.
• Cognitive effects and confusion. Can be mistaken for or worsen delirium, which is already common at end of life.
• Cardiovascular. THC raises heart rate and can precipitate angina or arrhythmia in patients with severe cardiac disease Strong evidence.
• Drug interactions. Especially with warfarin, tacrolimus, certain chemotherapies, and CNS depressants ^[7].
• Smoke inhalation. Worsens respiratory symptoms; vaporization or oral routes are preferred in palliative care.
• Acute psychiatric effects. Anxiety, paranoia, and rarely psychosis with high-THC products. Lower in CBD-dominant formulations.
• Tolerance and discontinuation. Less relevant in short-prognosis patients but worth considering in longer-term palliative care.

See also: THC, CBD, Cannabis and Cancer, Drug Interactions.

Sources

How this page was made